instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | SARS-CoV-2 Infection (COVID-19) and Herpes Simplex Virus-1 Conjunctivitis: Concurrent Viral Infections or a Cause-Effect Result?
The pulmonary effects of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), are well documented; however, more evidence is nee... | DOCETAXEL | DrugsGivenReaction | CC BY | 33575153 | 18,984,996 | 2021-01-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vitamin D deficiency'. | SARS-CoV-2 Infection (COVID-19) and Herpes Simplex Virus-1 Conjunctivitis: Concurrent Viral Infections or a Cause-Effect Result?
The pulmonary effects of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), are well documented; however, more evidence is nee... | DOCETAXEL | DrugsGivenReaction | CC BY | 33575153 | 18,984,996 | 2021-01-09 |
What was the outcome of reaction 'COVID-19'? | SARS-CoV-2 Infection (COVID-19) and Herpes Simplex Virus-1 Conjunctivitis: Concurrent Viral Infections or a Cause-Effect Result?
The pulmonary effects of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), are well documented; however, more evidence is nee... | Recovered | ReactionOutcome | CC BY | 33575153 | 18,984,996 | 2021-01-09 |
What was the outcome of reaction 'Ophthalmic herpes simplex'? | SARS-CoV-2 Infection (COVID-19) and Herpes Simplex Virus-1 Conjunctivitis: Concurrent Viral Infections or a Cause-Effect Result?
The pulmonary effects of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), are well documented; however, more evidence is nee... | Recovered | ReactionOutcome | CC BY | 33575153 | 18,984,996 | 2021-01-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'American trypanosomiasis'. | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | AZATHIOPRINE, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33575423 | 19,507,537 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | AZATHIOPRINE, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disseminated cytomegaloviral infection'. | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | AZATHIOPRINE, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Enterobacter infection'. | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | AZATHIOPRINE, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Septic shock'. | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | AZATHIOPRINE, PREDNISONE | DrugsGivenReaction | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
What was the outcome of reaction 'American trypanosomiasis'? | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | Recovering | ReactionOutcome | CC BY-NC-ND | 33575423 | 19,507,537 | 2021-02 |
What was the outcome of reaction 'Disseminated cytomegaloviral infection'? | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | Recovering | ReactionOutcome | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
What was the outcome of reaction 'Enterobacter infection'? | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | Fatal | ReactionOutcome | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
What was the outcome of reaction 'Septic shock'? | Reactivation of Chagas Disease in a Patient With an Autoimmune Rheumatic Disease: Case Report and Review of the Literature.
Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature describing reactivation in patients on immunosuppressive therapies for the trea... | Fatal | ReactionOutcome | CC BY-NC-ND | 33575423 | 19,494,598 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Transplant rejection'. | Safety and effectiveness of everolimus in maintenance kidney transplant patients in the real-world setting: results from a 2-year post-marketing surveillance study in Japan.
BACKGROUND
Data on real-world use of everolimus (EVR) in Japanese maintenance kidney transplant (KTx) patients are limited. This post-marketing su... | EVEROLIMUS, MYCOPHENOLATE MOFETIL, TACROLIMUS | DrugsGivenReaction | CC BY | 33575935 | 19,794,642 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood stem cell transplant failure'. | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | BUSULFAN, FLUDARABINE PHOSPHATE, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, MYCOPHENOLATE MOFETIL, TACROLIMUS, THIOTEPA | DrugsGivenReaction | CC BY | 33577809 | 19,010,959 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | FOSCARNET, GANCICLOVIR | DrugsGivenReaction | CC BY | 33577809 | 19,082,624 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | FOSCARNET, GANCICLOVIR | DrugsGivenReaction | CC BY | 33577809 | 19,082,624 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | BUSULFAN, FLUDARABINE PHOSPHATE, FOSCARNET, GANCICLOVIR, MYCOPHENOLATE MOFETIL, TACROLIMUS, THIOTEPA, THYMOCYTE IMMUNE GLOBULIN NOS | DrugsGivenReaction | CC BY | 33577809 | 19,141,715 | 2021-04 |
What was the dosage of drug 'BUSULFAN'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the dosage of drug 'FLUDARABINE PHOSPHATE'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the dosage of drug 'LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the dosage of drug 'TACROLIMUS'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the dosage of drug 'THIOTEPA'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | UNK UNK, UNKNOWN FREQ. | DrugDosageText | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the outcome of reaction 'Blood stem cell transplant failure'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the outcome of reaction 'Cystitis haemorrhagic'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,256,788 | 2021-04 |
What was the outcome of reaction 'Cytomegalovirus infection reactivation'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,256,788 | 2021-04 |
What was the outcome of reaction 'Cytomegalovirus infection'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,010,959 | 2021-04 |
What was the outcome of reaction 'Cytomegalovirus viraemia'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,009,259 | 2021-04 |
What was the outcome of reaction 'Pyrexia'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,090,951 | 2021-04 |
What was the outcome of reaction 'Transplant failure'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,256,788 | 2021-04 |
What was the outcome of reaction 'Viral haemorrhagic cystitis'? | Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report.
Human cytomegalovirus (HCMV) remains an important cause of transplant-related morbidity and mortality. The incidence of HCMV recurrence in t... | Recovered | ReactionOutcome | CC BY | 33577809 | 19,010,959 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study.
Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, lead... | CALCIUM, DENOSUMAB | DrugsGivenReaction | CC BY | 33579002 | 18,955,234 | 2021-02-10 |
What was the administration route of drug 'DENOSUMAB'? | Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study.
Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, lead... | Subcutaneous | DrugAdministrationRoute | CC BY | 33579002 | 18,955,234 | 2021-02-10 |
What was the outcome of reaction 'Death'? | Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study.
Denosumab is a human monoclonal antibody that neutralizes RANKL, a cytokine able to interact with the RANK receptor on preosteoclasts and osteoclasts, decreasing their recruitment and differentiation, lead... | Fatal | ReactionOutcome | CC BY | 33579002 | 18,955,234 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'American trypanosomiasis'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CYCLOSPORINE, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE | DrugsGivenReaction | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CARVEDILOL, CYCLOSPORINE, FUROSEMIDE, HYDRALAZINE HYDROCHLORIDE, HYDROCORTISONE, ISOSORBIDE, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, LEVOTHYROXINE, LOSARTAN, METHYLPREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemophagocytic lymphohistiocytosis'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CYCLOSPORINE, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE | DrugsGivenReaction | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Infection reactivation'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CYCLOSPORINE, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE | DrugsGivenReaction | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oxygen saturation decreased'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CARVEDILOL, CYCLOSPORINE, FUROSEMIDE, HYDRALAZINE HYDROCHLORIDE, HYDROCORTISONE, ISOSORBIDE, LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN, LEVOTHYROXINE, LOSARTAN, METHYLPREDNISOLONE, TACROLIMUS | DrugsGivenReaction | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | AZATHIOPRINE, CYCLOSPORINE, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE | DrugsGivenReaction | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the dosage of drug 'METHYLPREDNISOLONE SODIUM SUCCINATE'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | UNK (PULSE METHYLPREDNISOLONE) | DrugDosageText | CC BY | 33579042 | 19,731,501 | 2021-02-10 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | PULSE METHYLPREDNISOLONE | DrugDosageText | CC BY | 33579042 | 19,816,778 | 2021-02-10 |
What was the outcome of reaction 'Acute respiratory distress syndrome'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'American trypanosomiasis'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'COVID-19'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,816,778 | 2021-02-10 |
What was the outcome of reaction 'Cardiogenic shock'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'Chronic kidney disease'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Disseminated cytomegaloviral infection'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Dyspnoea'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Haemophagocytic lymphohistiocytosis'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'Infection reactivation'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'Lymphopenia'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Multiple organ dysfunction syndrome'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Oxygen saturation decreased'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
What was the outcome of reaction 'Pancytopenia'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'Septic shock'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,731,502 | 2021-02-10 |
What was the outcome of reaction 'Thrombocytopenia'? | SARS-CoV-2 Infection and CMV Dissemination in Transplant Recipients as a Treatment for Chagas Cardiomyopathy: A Case Report.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a... | Fatal | ReactionOutcome | CC BY | 33579042 | 19,681,859 | 2021-02-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Hypermutated phenotype in gliosarcoma of the spinal cord.
Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal glios... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY | 33580181 | 19,179,073 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gliosarcoma'. | Hypermutated phenotype in gliosarcoma of the spinal cord.
Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal glios... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY | 33580181 | 18,945,561 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypermutation'. | Hypermutated phenotype in gliosarcoma of the spinal cord.
Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal glios... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY | 33580181 | 19,179,073 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Hypermutated phenotype in gliosarcoma of the spinal cord.
Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal glios... | TEMOZOLOMIDE | DrugsGivenReaction | CC BY | 33580181 | 18,945,561 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE, BUPRENORPHINE, DOCETAXEL | DrugsGivenReaction | CC BY | 33580193 | 19,460,717 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE, BUPRENORPHINE, DOCETAXEL | DrugsGivenReaction | CC BY | 33580193 | 19,460,717 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dysgeusia'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung adenocarcinoma'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use issue'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | DABRAFENIB, OSIMERTINIB, TRAMETINIB | DrugsGivenReaction | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
What was the administration route of drug 'ACETAMINOPHEN\OXYCODONE HYDROCHLORIDE'? | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | Oral | DrugAdministrationRoute | CC BY | 33580193 | 19,460,717 | 2021-02-12 |
What was the outcome of reaction 'Pyrexia'? | Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
The survival outcomes of the FLAURA trial support osimertinib as the new standard of care for untreated patients harboring activating mutations in the epidermal growth factor receptor (EGFR... | Recovered | ReactionOutcome | CC BY | 33580193 | 19,431,708 | 2021-02-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | AMIKACIN SULFATE, BUDESONIDE, CEFOPERAZONE, CEFTRIAXONE, CIPROFLOXACIN, FENOTEROL, FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE, IPRATROPIUM BROMIDE, METHOTREXATE, PREDNISOLONE, TIOTROPIUM BROMIDE | DrugsGivenReaction | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Klebsiella infection'. | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | BUDESONIDE, FENOTEROL, FLUTICASONE PROPIONATE, IPRATROPIUM BROMIDE, METHOTREXATE, PREDNISOLONE, SALMETEROL, TIOTROPIUM BROMIDE | DrugsGivenReaction | CC BY-NC-ND | 33582702 | 18,975,017 | 2021-02-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | BUDESONIDE, FENOTEROL, FLUTICASONE PROPIONATE, IPRATROPIUM BROMIDE, METHOTREXATE, PREDNISOLONE, SALMETEROL, TIOTROPIUM BROMIDE | DrugsGivenReaction | CC BY-NC-ND | 33582702 | 18,975,017 | 2021-02-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sputum purulent'. | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | AMIKACIN SULFATE, BUDESONIDE, CEFOPERAZONE, CEFTRIAXONE, CIPROFLOXACIN, FENOTEROL, FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE, IPRATROPIUM BROMIDE, METHOTREXATE, PREDNISOLONE, TIOTROPIUM BROMIDE | DrugsGivenReaction | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | AMIKACIN SULFATE, BUDESONIDE, CEFOPERAZONE, CEFTRIAXONE, CIPROFLOXACIN, FENOTEROL, FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE, IPRATROPIUM BROMIDE, METHOTREXATE, PREDNISOLONE, TIOTROPIUM BROMIDE | DrugsGivenReaction | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
What is the weight of the patient? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | 82 kg. | Weight | CC BY-NC-ND | 33582702 | 18,962,204 | 2021-02-14 |
What was the administration route of drug 'AMIKACIN'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the administration route of drug 'BUDESONIDE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 19,021,629 | 2021-02-14 |
What was the administration route of drug 'CEFOPERAZONE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the administration route of drug 'CEFTRIAXONE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the administration route of drug 'CIPROFLOXACIN'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the administration route of drug 'FENOTEROL'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 19,021,629 | 2021-02-14 |
What was the administration route of drug 'FLUTICASONE PROPIONATE\SALMETEROL XINAFOATE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Respiratory (inhalation) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the administration route of drug 'IPRATROPIUM BROMIDE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Respiratory (inhalation) | DrugAdministrationRoute | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the dosage of drug 'AMIKACIN SULFATE'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | 1 G, PER DAY | DrugDosageText | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
What was the dosage of drug 'FENOTEROL'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | NEBULIZED 2000 UG PER DAY | DrugDosageText | CC BY-NC-ND | 33582702 | 18,975,017 | 2021-02-14 |
What was the dosage of drug 'METHOTREXATE SODIUM'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | 25 MG, WEEKLY | DrugDosageText | CC BY-NC-ND | 33582702 | 18,986,917 | 2021-02-14 |
What was the dosage of drug 'TIOTROPIUM'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | 18 µg (micrograms). | DrugDosage | CC BY-NC-ND | 33582702 | 18,962,204 | 2021-02-14 |
What was the outcome of reaction 'Asthma'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
What was the outcome of reaction 'Disease progression'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
What was the outcome of reaction 'Drug ineffective'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,986,567 | 2021-02-14 |
What was the outcome of reaction 'Klebsiella infection'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,975,017 | 2021-02-14 |
What was the outcome of reaction 'Pneumonia klebsiella'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,962,204 | 2021-02-14 |
What was the outcome of reaction 'Pneumonia'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,962,812 | 2021-02-14 |
What was the outcome of reaction 'Respiratory failure'? | Case Report: A 64-Year-Old Man with 10-Year History of Eosinophilic Granulomatosis with Polyangiitis with Bronchiectasis and Severe Klebsiella pneumonia.
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and severe progressive disease with multiple clinical manifestations and organ damage. Usual... | Fatal | ReactionOutcome | CC BY-NC-ND | 33582702 | 18,986,917 | 2021-02-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthenia'. | Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.
Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-... | ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC | 33582978 | 18,969,138 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Device related infection'. | Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.
Atezolizumab is a monoclonal antibody targeting the programmed death ligand 1 (PD-L1) that was approved in 2017 in the USA and Europe for the second-line treatment of advanced or metastatic non-... | ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC | 33582978 | 18,610,802 | 2021-06 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.